The pharmaceutical industry faces a perfect storm, with unsustainable growth in healthcare costs, increasing costs of drug discovery, and the shift to a value-based payment model.
The benefits of adherent patients are no secret: better outcomes, a more stable treatment pathway and of course better revenues for pharma are all possible.
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat